Among healthcare professionals there is no consensus about the best policy to increase oral intake and promote recovery in the post-hospital phase after bone marrow or blood stem cell transplantation. In order to evaluate body weight recovery and compliance with dietary advice among these patients, we performed a prospective longitudinal study in the first year post transplant. At five time intervals (days 50, 75, 125, 200 and 350) patients received a nutritional questionnaire with items on nutrition-related symptoms, physical condition, body weight recovery and compliance with dietary advice. From the initial cohort of 135 patients 69 completed the study. Prevalence of eating difficulties was high (66% at day 50). Anorexia, dry mouth, altered taste, nausea and tiredness were the symptoms most strongly associated with eating difficulties. Compliance with dietary advice was poor. Conditioning regimen was found to be a prognostic factor for body weight status at day 350. In more than 50% of the TBI-treated patients body weight was not restored to 95% of the pretreatment value within 1 year after transplant. Future studies should focus on increasing energy and protein intake in the TBI-treated subgroup. Bone Marrow Transplantation (2002) 29, 417-424. DOI: 10.1038/sj/bmt/1703375 Keywords: body weight; gastro-intestinal complaints; nutrition; oral supplements; dietary compliance Current indications for bone marrow transplantation (BMT) and peripheral blood cell transplantation (BCT) include not only haematological malignancies but also solid tumours (breast carcinoma, childhood sarcomas) and non-malignant diseases such as scleroderma. The spectrum of conditioning
and treatment regimen has expanded to include a great number of schedules varying in combinations and dosages of cytotoxic agents, inclusion of total body irradiation (TBI), donor type and recruitment procedure of stem cells (peripheral or bone marrow). Gastro-intestinal side-effects such as nausea, mouth complaints and anorexia are common with all treatment modalities, although severity and duration may differ per conditioning regimen.
As the effects of toxicity may reduce oral intake for a prolonged period of time, monitoring of nutritional status and nutritional intake is an essential part of supportive care for patients receiving BMT or BCT. Over the past decade there have been several publications [1] [2] [3] [4] [5] on nutritional support strategies during the clinical treatment phase of blood cell transplant recipients. Less attention has been paid to body weight recovery and eating problems in the post-hospital phase. [6] [7] [8] [9] Lenssen et al 6 reported nutritional problems in 23% and weight loss in 28% of 192 patients in the first year after allogeneic bone marrow transplantation. Chao et al 7 found that at 90 days post transplant about one-third of patients reported poor appetite. In practice, there is no consensus among healthcare professionals about the best policy to increase oral intake and promote recovery in the post-hospital phase. Some consider eating problems in this phase as transient and pay little attention to them, while others 9 choose invasive procedures such as home parenteral nutrition to guarantee nutrient provision. The policy at the Department of Haematology of the Leiden University Medical Centre is to educate patients during their in-hospital period on how to enhance the nutritional value of their diet by choosing food constituents with either a high protein or energy density or by taking oral nutritional supplements. At discharge, patients are advised to monitor their body weight and enhance their energy and protein intake according to their individual needs. Dietary follow-up consults in the post-hospital phase are provided on request of the patient or his physician.
In order to evaluate the nutritional aspects of the recovery process and compliance with dietary advice given at discharge, we performed a prospective longitudinal study on body weight recovery, prevalence of eating problems and compliance with dietary advice in the first year post transplant. We were especially interested in prognostic factors which might help select patients needing more intensive counselling in the post-discharge phase.
Patients and methods

Patients
All consecutive patients who were discharged after receiving BMT or BCT at the Department of Haematology of the Leiden University Medical Centre (LUMC) between May 1996 and November 1998 were eligible. Treatment indications were: leukaemia (acute myeloid, acute lymphoblastic and chronic myeloid leukaemia), multiple myeloma, lymphoma (Burkitt's, Hodgkin's and non-Hodgkin's lymphoma), solid tumours (breast carcinoma, testis carcinoma and soft tissue sarcoma) and a few miscellaneous conditions (aplastic anaemia, thalassemia, scleroderma). Inclusion criteria were informed consent and ability to understand written Dutch. Due to the compromised physical condition of the patients and the high risk of relapse or other fatal complications in the first year after transplantation a high dropout rate (50%) was expected. In order to have at least 75 evaluable patients, we planned to include 150 patients.
Conditioning procedures
The pretransplant conditioning regimens for leukaemia, aplastic anaemia and multiple myeloma consisted of cyclophosphamide and total body irradiation followed by autologous or allogeneic (matched or mismatched) blood cell or bone marrow transplantation; for lymphoma of BCNU, etoposide and cytarabine followed by autologous blood cell or bone marrow transplantation (BEAC regimen); for breast carcinoma of carboplatin, cyclophosphamide and thiopeta followed by autologous blood cell transplantation; for Ewing sarcoma of carboplatin, etoposide and melphalan followed by autologous blood cell or bone marrow transplantation and for scleroderma of cyclophosphamide followed by autologous blood cell transplantation.
Nutritional counselling
During hospital stay daily oral food intake was recorded three times a week and nutritional counselling focused on improving oral energy and protein intake. The goal for energy intake during the in-hospital period was: 130% of the outcome of the Harris-Benedict equation, 10 for protein intake 1.3 g/kg and for micronutrients the Recommended Daily Intake.
11 In these calculations actual body weight was used for non-obese patients. For obese patients (BMI Ͼ 25 kg/m 2 ) the adjusted ideal body weight was used (calculated as body weight value for BMI ϭ 25 kg/m 2 plus 0.25 ϫ the difference between this value and actual body weight). 8 During their stay in hospital patients were educated on their individual nutritional requirements and on products with a high energy or protein density. Patients were advised to comply with general healthy diet advice 12 to guarantee their micronutrient intake. In cases of prolonged reduced intake, milkshakes and commercial supplements (protein-rich drinks or powder fortified with vitamins and minerals) were introduced and information was provided on how to prepare them or where to buy them at home. The use of micronutrient preparations was not advocated, because a combined provision of energy, protein and other nutrients was preferred. At discharge from hospital patients received a written summary of the nutritional information given during their stay. Patients were advised to continue monitoring their daily intake and body weight and enrich their home diet according to their individual needs. They were encouraged to contact their dietician when necessary.
Study procedure
The Medical Ethics Committee of the LUMC approved the research protocol. Written information about the study was given to the patients and informed consent was obtained some days prior to their discharge from hospital. Medical information such as diagnosis and type of transplant was collected from the case report forms completed by the physicians. A nutritional questionnaire was sent at five time points during the post-transplantation year and was accompanied by an explanatory letter and a stamped return envelope.
Measurement points
At five time points in the first year after transplantation (days 50, 75, 125, 200 and 350 post transplantation) patients were asked to measure their body weight and to complete a nutritional questionnaire. The time points were chosen to reflect stages in the recovery process: most patients are discharged before day 50, the highest prevalence of nutrition-related problems is expected at days 75 and 125, immunosuppressive therapy (allogeneic transplants only) is withdrawn in most cases before day 200 and nutritional status is assumed to be close to the pre-morbid state at day 350. Pre-treatment body weight was measured before the start of conditioning between days Ϫ10 and Ϫ2 before transplantation. (In the figures with body weight recovery patterns pre-treatment value is noted at day 0 for layout technical reasons.)
Instrument
The questionnaire was designed based upon known sideeffects that were expected to interfere with adequate nutrient intake. An expert panel tested face validity. Reference period was the last 14 days before the day that the questionnaire was completed. The first item questioned the occurrence of 'eating difficulties'. The next item explored the frequency and duration of 17 nutrition-related side-effects and complications (decreased appetite, increased appetite, sore mouth, dry mouth, altered taste, painful chewing, painful swallowing, heart burn, nausea, retching, vomiting, gut complaints, more frequent defecation, less frequent defecation, more solid stool, more liquid stool, tiredness). Subsequently, patients were asked to report their actual body weight, the mean number of resting hours per 24 h and a subjective score for their physical well-being (range 1-10).
Open-ended questions were added in order to acquire insight into adaptations patients made to cope with these problems and their compliance with dietary advice. These questions concerned changes in food volume, food consistency, food avoidances and actions taken to enrich the energy, protein or micro-nutrient content of the menu. Cronbachs alpha for the 12 items related to the severity of eating difficulties was 0.74 indicating a good internal consistency. Predictive validity was satisfying, since the number of episodes with eating difficulties and the number of episodes with inadequate intake correlated Ϫ0.38 (P Ͻ 0.05) and Ϫ0.49 (P Ͻ 0.01) with body weight status at day 350.
Definition of outcome parameters
Body weight status (expressed as % of pre-treatment) and the presence of eating difficulties at the various time points were chosen as primary outcome parameters. A period with a specific symptom was defined as the presence of the symptom for more than 2 days during the last fortnight. A period of inadequate food intake was defined as a period of more than 2 days during the last fortnight with at least one of the following sentences being true: 'I had no intake at all', 'I used only liquids' or 'I used only half or less of my usual amount'. Dietary compliance was defined as being present when patients reported relevant actions in response to one of the following questions: 'what did you do to enrich your diet with energy/protein/micronutrients?'.
Statistics
Study participants consisted of study completers (those who remained in the study until the end), dropouts (those who left the study before day 350) and non-responders (no questionnaires returned). Not all data sets of the study completers were fully completed. In some longitudinal analyses only data of complete responders (those who completed and returned all five questionnaires) were included.
Four analyses were performed: First, we described the characteristics of our study population and differences between study completers and dropouts. Secondly, we studied longitudinal data of all available patients by using mixed-model analyses of variance to describe the body weight recovery pattern. Also, prevalence and duration of symptoms and diet compliance was described. Differences in time and differences between study completers and dropouts were tested by chi-square tests. Thirdly, in order to identify what baseline characteristics were prognostic for a body weight status of less than 95% of pre-treatment value at day 350, we performed a logistic regression analysis. In this analysis y was body weight status at day 350 (yes or no у95% of baseline) and x were all baseline characteristics. Fourthly, we compared longitudinal data about body weight recovery, eating difficulties, symptoms and compliance with dietary advice between subgroups determined by the prognostic factors. For this analysis we used data of the complete responders.
Parametric statistical measures were used for variables that were normally distributed. For non-normally distribBone Marrow Transplantation uted variables non-parametric statistical measures were used. The level of statistical significance was set at P р 0.05.
Results
Study population
Out of 161 consecutive patients who received BCT or BMT at the Leiden University Medical Centre between May 1996 and November 1998 a cohort of 135 (69 men and 66 women) entered the study. Twenty-six patients were excluded: due to early death (n ϭ 9), illiteracy (n ϭ 1), insufficient knowledge of the Dutch language (n ϭ 6), poor mental condition (n ϭ 1), no informed consent obtained (n ϭ 5), planned re-hospitalisation within the study period for second stem cell infusion (n ϭ 1) or organisational reasons (n ϭ 3). During the 1-year follow-up period of the initial cohort of 135 patients 17 patients did not return any questionnaire (non-responders), 49 patients left the study before day 350 (dropouts) and 69 patients completed the study (study completers). Complete data sets were available for 58 patients (complete responders). A total of 440 questionnaires was returned. Response rate at day 50 was 74% (n ϭ 100), at day 75 76% (n ϭ 103), at day 125 64% (n ϭ 87), at day 200 60% (n ϭ 81) and at day 350 51% (n ϭ 69). Reasons for non-response in the groups of dropouts and non-responders were death, relapse, worsening physical condition, psychological distress or unknown. Table 1 shows population characteristics of study completers, dropouts and non-responders. Groups differed with respect to age (dropouts and non-responders were younger), conditioning regimen (more patients treated with TBI dropped out) and donor (more recipients of an allogeneic transplant dropped out). No significant differences were seen with respect to gender ratio, diagnosis, type of transplant, pre-treatment body mass index, length of hospital stay or weight loss during admission.
Longitudinal data
Body weight recovery was analysed in all available patients (n ϭ 118) using mixed-model analysis of variance. Average body weight status was 93% at day 50, 91% at day 75, 92% at day 125, 93% at day 200 and 94% at day 350. There was, however, an important difference between patients who completed, and those who dropped out. Figure  1 shows the body weight recovery curve of both study completers (n ϭ 69) and dropouts (n ϭ 49). For the study completers body weight kept falling until day 75 to 92% of pre-treatment value. After day 75 mean body weight slowly recovered to 94% of pre-treatment value at day 350. At all measurement points body weight value of the dropouts was lower compared to that of the study completers. For days 125 and 200 this difference was statistically significant (P Ͻ 0.05). Table 2 shows the prevalence of eating difficulties and nutrition-related symptoms at the five time points. The question 'Have you had any eating difficulties in the last 2 weeks?' was answered with yes in 66% of the study com- pleters at day 50. At day 350 eating difficulties were still present in 22% of the cases. Of 17 nutrition-related sideeffects, poor appetite, dry mouth, taste alterations, nausea and tiredness were the most frequent complaints and were also most strongly associated with the presence of eating difficulties. The correlation with eating difficulties was highest for poor appetite (r ϭ 0.76, P Ͻ 0.01). Poor appetite was present in 65% of the study completers at day 50 and remained in 9% at day 350. Dry mouth complaints were also frequent (56%) at day 50 and disappeared slowly (still 20% at day 350). Taste alterations occurred in 61% of the patients at day 50 and remained in 7% at day 350. Nausea was seen most in the first months (37% at day 50) and almost disappeared after day 125 (3% at day 350). Tiredness had the highest frequency at the start (85%) and still occurred in 43% of the patients at day 350. Other symptoms such as sore mouth, chewing and swallowing problems, heartburn, gut complaints and altered defecation patterns occurred in less than 20% of the cases at all time points. The prevalence of all symptoms was higher in dropouts than in study completers. Complaints about poor appetite and dry mouth were significantly more often (P Ͻ 0.05) reported by dropouts than by study completers.
In the second part of Table 2 , data are shown on the presence of inadequate intake and actions taken to enrich the nutritional value of the diet. Especially in the first three c Dropouts (n ϭ 49; day 50 n ϭ 38; day 75 n ϭ 35; day 125 n ϭ 23; day 200 n ϭ 14; day 350 n ϭ 0). *Significant differences between groups (P Ͻ 0.01).
measurement points, many patients (42% at day 50, 32% at day 75 and 17% at day 125) reported having had an inadequate food intake ('eaten half or less than usual') for more than 2 days in the preceding fortnight. At day 50, 42% of the study completers reported having taken special actions to enrich energy content of their diet, 29% to enrich protein content and 35% to enrich micronutrient content of their diet. Frequency of energy and protein enrichments decreased to 25% at day 75. For micronutrient enrichments the percentage remained about 30% throughout the study. Commercial energy and protein supplements (data not shown) were used
Bone Marrow Transplantation by less than 10% of the study population at each time point. Commercial micronutrient preparations were used in about 15-30% of the patients throughout the year. The number of patients that actively enriched their diet was not significantly different in study completers and dropouts. The number of resting hours per 24 h and a self-report subjective score for 'well-being' improved significantly in time (from 11 resting h at day 50 to 9 h at day 350 and from a well-being score of 5.5 at day 50 to 6.8 at day 350). Study completers reported a lower number of resting hours and a higher score for well-being than dropouts.
Prognostic factors
In order to determine what baseline characteristics were prognostic for successful body weight recovery, we split the group into good and bad performers. Good performers were defined as those who kept or regained at least 95% of their pre-treatment weight at day 350. Body weight value of the bad performers was below 95% of baseline at day 350. We compared baseline characteristics of good (n ϭ 36) and bad (n ϭ 33) performers and found that of all baseline characteristics only initial Body Mass Index (BMI) and conditioning regimen were significantly different between groups. Initial BMI was 26.5 Ϯ 4.1 for the bad performers vs 23.5 Ϯ 5.0 for the good performers (P Ͻ 0.01; Student's t-test). Conditioning included TBI in 67% of the bad performers vs 42% in the good performers (P Ͻ 0.05, chisquare). Since the presence of overweight at baseline might interact with full restoration of pre-treatment body weight, we performed logistic regression analysis to correct for this effect. After adjustment for pre-treatment overweight (defined as BMI Ͼ 25 kg/m 2 ), conditioning regimen (with or without TBI) was the only baseline characteristic that contributed significantly to predicting classification of body weight status at day 350 (P Ͻ 0.05; percent correct classification of the model 68%).
Subgroups
Body weight recovery was analysed for four subgroups characterised by pre-treatment body weight status and conditioning regimen using data of all available patients (n ϭ 118) in a mixed-model analysis of variance. Figure 2 shows body weight recovery curves of the four subgroups. Differences between groups with the same pre-treatment body weight classification but different conditioning regimen (with or without TBI) were statistically significant at all time points after day 50.
The percentage of normal weight patients treated without TBI who had at least 95% of their pre-treatment body weight was 58% at day 50, 64% at day 75, 68% at day 125, 83% at day 200 and 88% at day 350. For normal weight patients treated with TBI this percentage was 36% at day 50, 20% at day 75, 28% at day 125, 41% at day 200 and 48% at day 350. We used data of 58 complete responders to compare longitudinal data on eating difficulties and symptoms between subgroups treated with and without TBI. Table 3   Table 3 Patient characteristics of two subgroups of complete responders (n ϭ 58) shows baseline data of subgroups treated with and without TBI. Groups differed significantly with respect to diagnosis (more leukaemia and multiple myeloma in the ϩTBI group), donor type (more allogeneic transplants in the ϩTBI group), length of hospital stay (longer stay in the ϩTBI group) and weight loss between baseline and discharge from hospital (more weight loss in the ϩTBI group). Patients with pre-treatment overweight were equally distributed among the two groups. Table 4 shows the median number of measurements (0-5) with eating difficulties, symptoms or inadequate food intake or dietary adaptations. Between groups, a significant difference is seen in the number of episodes with eating difficulties, poor appetite, dry mouth complaints and inadequate intake. No statistical difference was seen for the number of episodes of taste alterations, nausea, tiredness or actions to enrich the diet.
Discussion
This study was performed to evaluate nutritional aspects of the recovery process and compliance with dietary advice in a heterogeneous patient group in the first year after blood stem cell transplantation. We found that only half of the patients regained at least 95% of their pre-treatment body weight. After adjusting for pre-existing overweight we found that this percentage was 88% in patients treated without TBI and 48% in patients treated with TBI. Retarded weight recovery in the TBI-treated groups was accompanied by lengthier episodes of experiencing poor appetite, dry mouth and inadequate food intake compared to the non-TBI group. Compliance with dietary advice was poor. At day 50 about 42% of the patients reported having enriched the energy content of their diet, but this percentage diminished sharply with time. For protein enrichments the percentage was even lower. No significant differences in compliance were seen between the groups treated with and without TBI, although -looking at their weight recovery curve -TBI-treated patients should have had more reasons to enrich their diet. From all commercial oral supplements Table 4 Median number of episodes with eating difficulties, symptoms and diet adaptations in two subgroups of 58 complete responders Bone Marrow Transplantation micronutrient preparations were more popular than energy, protein supplements or combined preparations.
As expected in this patient population, response rate in this study was low (43%). Explanatory factors are the poor physical condition of the patients and a mortality rate within 1 year after discharge of 25% of all responders (n ϭ 118). Study completers were not comparable to dropouts and non-responders with respect to baseline characteristics (more low risk patients in the completers group) and outcome (higher values for body weight and a lower frequency of symptoms and inadequate food intake in the completers group). This limits generalizability of our results. We conclude that our rather negative findings, might still give an over positive view of the recovery process and frequency of nutritional problems after blood cell transplantation in a miscellaneous patient population.
With respect to data quality, we assessed internal consistency and predictive validity. Internal consistency was satisfactory with a Cronbach's alpha of 0.74. Predictive validity was satisfactory with correlation coefficients for body weight status at day 350 and the number of episodes with eating difficulties or inadequate intake of Ϫ0.38 and Ϫ0.49, respectively. We conclude that our data give a reliable view of the body weight recovery process and its related problems.
Earlier reports note the prevalence of eating difficulties after discharge from hospital. Lenssen et al 6 reported nutritional problems in 23%, and weight loss in 28% of 192 patients in the first year after allogeneic bone marrow transplantation. Chao et al 7 reported that at 90 days post transplant about one-third of patients reported poor appetite. The prevalence in our patient group was higher, probably due to the fact that our measurements were more frequent (five times) and our first measurement (day 50) was earlier in the recovery phase. The fact that only a minority of patients appears to regain their pre-morbid nutritional status at day 350 is also reported by Schulte et al. 13 They found in a group of 100 stem cell transplant recipients with haematological malignancies that the survivors after 1 year did not regain their pre-transplant physical condition, showed lower body weights, decreased muscle mass and grip strength as compared to baseline. We did not find any study that shed light on the dietary intake and compliance with dietary advice in the first year post transplant.
While the present study is one of the first studies that focuses on body weight recovery and compliance with dietary advice in the first year post transplant, several weaknesses in this study should be addressed in future research. First, numbers were small, especially in the subgroup analyses. This implies that we might have missed relevant differences that could have been picked up in a bigger sample size. We suggest that more prognostic research in larger groups, especially in patients treated with TBI might be helpful in understanding what factors can improve nutritional outcome in this group. Secondly, compliance with dietary advice has been measured by open-ended questions. This might have resulted in underreporting. Also information on individuals' need for enrichments was missed because we had no quantitative information on the individuals' intake. We suggest that addition of a food rec-ording method might be a useful tool in future studies. Thirdly, weight loss and retarded recovery in the post-transplant phase are multi-factorial. Unfortunately, several factors which might underlie this problem were not assessed in this study. For example, complications, prevalence of graft-versus-host disease, supportive care measures (such as anti-emetic medication etc) and social factors deserve attention in future studies. Fourthly, all data were selfreported. Addition of observational data as a crosscheck would strengthen future research.
In conclusion, our study revealed that eating difficulties and retarded weight recovery in the first year post transplant are relevant problems, especially in the TBI-treated group. TBI-treated patients need more attention after discharge with respect to their intake and nutritional status. We suggest that screening of intake and nutritional status should be routinely performed in this patient group around day 75. Compliance with dietary advice can possibly be improved by refreshing the information at that time. Clear information on the value of micronutrient supplementation and combined preparations with protein and energy is required. More insight into the reasons why the use of commercial oral energy and protein supplements is low in this patient population might challenge future research.
